Prev Close | 32.16 |
Open | 31.67 |
Day Low/High | 30.32 / 31.75 |
52 Wk Low/High | 2.20 / 41.65 |
Volume | 457.66K |
Prev Close | 32.16 |
Open | 31.67 |
Day Low/High | 30.32 / 31.75 |
52 Wk Low/High | 2.20 / 41.65 |
Volume | 457.66K |
Exchange | NASDAQ |
Shares Outstanding | 193.10B |
Market Cap | 6.47B |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.
Cantor Fitzgerald says Illumina's outlook revision is not likely to affect industry peers.
Despite the tepid open, I'm participating with a position in SSO and PACB's chart still looks good.
The gap-up open quickly faded, and there is no buying traction at all, right now.
A strong open doesn't always produce greater clarity.
Indices are the way so far in today's challenging market.
There are a number of forces at play in market carnage.
With such a commanding lead in the sequencing business the stock can't stay down for long.
Washington will offer mixed bag answers to key policy questions.
Four small-caps I have an eye on.
But how long will it last?